MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tolner, B.
Right arrow Articles by Hochhauser, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tolner, B.
Right arrow Articles by Hochhauser, D.

Vol. 59, Issue 4, 699-706, April 2001

Transcriptional Regulation of Topoisomerase IIalpha at Confluence and Pharmacological Modulation of Expression by bis-Benzimidazole Drugs

Berend Tolner, John A. Hartley, and Daniel Hochhauser

CRC Drug-DNA Interactions Research Group (J.A.H.), Department of Oncology (B.T., J.A.H., D.H.), Royal Free and University College Medical School, University College London, Gower Street Campus, London, United Kingdom

Topoisomerase IIalpha is a critical gene involved in DNA replication and maintenance of genomic stability. Several chemotherapeutic agents target topoisomerase II and levels of expression are an important factor in chemosensitivity. Transcriptional regulation has been demonstrated to regulate topoisomerase IIalpha levels under several circumstances, including cellular confluence, heat shock, and expression of oncogenes including ras and myb. Expression of topoisomerase IIalpha is regulated by cellular proliferation; transcriptional down-regulation in confluent cells is modulated through sequences within the promoter. In this study, we examined DNA-protein interactions within the topoisomerase IIalpha promoter in exponential and confluent phase NIH3T3 cells. Using electrophoretic mobility shift assay and in vitro DNase I footprint experiments, the involvement of NF-Y in transcriptional regulation was established. Incubation of the DNA minor groove-binding agents Hoechst 33342 and Hoechst 33258 with nuclear extracts revealed drug binding to regions surrounding the inverted CCAAT boxes within the topoisomerase IIalpha promoter and displacement of proteins binding to these elements. Addition of both Hoechst 33342 and Hoechst 33258 to NIH3T3 cells at confluence resulted in increased expression of topoisomerase IIalpha . In addition, MTT cytotoxicity assays in confluent cells showed an additive effect of incubation with Hoechst 33342 and the topoisomerase IIalpha poison etoposide. Therefore, DNA binding drugs which block transcription factor activation of the promoter may deregulate topoisomerase IIalpha and this strategy may be of value in modifying gene expression and modulating chemosensitivity.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
M. Kotecha, J. Kluza, G. Wells, C. C. O'Hare, C. Forni, R. Mantovani, P. W. Howard, P. Morris, D. E. Thurston, J. A. Hartley, et al.
Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78
Mol. Cancer Ther., May 1, 2008; 7(5): 1319 - 1328.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
T. Ellis, D. A. Evans, C. R. H. Martin, and J. A. Hartley
A 96-well DNase I footprinting screen for drug-DNA interactions
Nucleic Acids Res., June 22, 2007; (2007) gkm467v1.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Hochhauser, M. Kotecha, C. O'Hare, P. J. Morris, J. M. Hartley, Z. Taherbhai, D. Harris, C. Forni, R. Mantovani, M. Lee, et al.
Modulation of topoisomerase II{alpha} expression by a DNA sequence-specific polyamide
Mol. Cancer Ther., January 1, 2007; 6(1): 346 - 354.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
N Mohorko, N Kregar-Velikonja, G Repovs, M Gorensek, and M Bresjanac
An in vitro study of Hoechst 33342 redistribution and its effects on cell viability
Human and Experimental Toxicology, November 1, 2005; 24(11): 573 - 580.
[Abstract] [PDF]

Home page
 J BiochemHome page
M. Saito, M. Kobayashi, S.-i. Iwabuchi, Y. Morita, Y. Takamura, and E. Tamiya
DNA Condensation Monitoring after Interaction with Hoechst 33258 by Atomic Force Microscopy and Fluorescence Spectroscopy
J. Biochem., December 1, 2004; 136(6): 813 - 823.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. U. Kurz, S. E. Wilson, K. B. Leader, B. P. Sampey, W. P. Allan, J. C. Yalowich, and D. J. Kroll
The Histone Deacetylase Inhibitor Sodium Butyrate Induces DNA Topoisomerase II{alpha} Expression and Confers Hypersensitivity to Etoposide in Human Leukemic Cell Lines
Mol. Cancer Ther., December 1, 2001; 1(2): 121 - 131.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics